JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

Benzinga Newsdesk www.benzinga.com Positive 80.4%

Neg 0% Neu 0% Pos 80.4%

JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.